Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolZeljko Reiner, Gregory G. Schwartz, Vera A. Bittner et al.|Journal of the American College of Cardiology|2021Cited by 143
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of AlirocumabEmil Hagström, Patricio López‐Jaramillo, Deepak L. Bhatt et al.|Circulation|2022Cited by 123